Core Insights - The Phase 3 TALAPRO-3 study demonstrated that TALZENNA in combination with XTANDI significantly improves radiographic progression-free survival in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer [1][2][5] Study Results - The study met its primary endpoint, showing a statistically significant improvement in radiographic progression-free survival compared to placebo plus XTANDI, with a hazard ratio of 0.63 [2][5] - A strong trend toward improved overall survival was observed at the time of interim analysis, along with benefits in secondary endpoints such as overall response rate and duration of response [3][5] Patient Population - Prostate cancer is the second most common cancer in men globally, with an estimated 1.4 million new cases diagnosed in 2022 and 330,000 new cases expected in the U.S. in 2026 [4] - Approximately 25% of metastatic prostate cancers have alterations in DNA damage repair genes, which are associated with worse prognosis and higher progression rates [6] Regulatory and Market Implications - The results will be discussed with global health authorities to potentially expand the indication for TALZENNA in earlier stages of the disease [5][6] - TALZENNA plus XTANDI is already approved in 60 countries for HRR gene-mutated metastatic castration-resistant prostate cancer [7][12] Clinical Trial Details - The TALAPRO-3 trial enrolled 599 patients with mCSPC and was a multicenter, randomized, double-blind, placebo-controlled study [8] - The primary endpoint was investigator-assessed radiographic progression-free survival, with secondary endpoints including overall survival and patient-reported outcomes [9]